Skip to main content
. 2013 May 14;2(3):237–246. doi: 10.2217/cns.13.12

Figure 2. Survival of diabetic glioblastoma patients.

Figure 2.

(A) Comparison of overall survival between diabetic (n = 123; 10 months; 95% CI: 8–12) and nondiabetic (n = 864; 13.4 months; 95% CI: 12.7–14.4) glioblastoma patients (log rank = 0.0000). (B) Comparison of overall survival between patients who had a diagnosis of diabetes at baseline (n = 89) and those who developed diabetes in the setting of steroid use for treatment of glioblastoma (n = 34; log rank = 0.5). (C) Comparison of overall survival between diabetic patients who were able to be tapered off steroids (n = 18; 17 months; 95% CI: 9–25) and those who remained steroid dependent (n = 102; 9 months; 95% CI: 8–11; log rank = 0.05). (D) Comparison of overall survival based on median glucose values divided into tertiles: median glucose 98.5–173 mg/dl (n = 33; 11 months; 95% CI: 9–17); 174–247 mg/dl (n = 76; 9 months; 95% CI: 7–12); and >247 mg/dl (n = 14; 8 months; 95% CI: 2–26; log rank = 0.36).